Yang Yang, PhD

• Alessandro Santin
• Alla Vash-Margita
• Gloria Huang
• Masoud Azodi
• Melinda Irwin
• Mitchell Clark
• Natalia Buza
• Pei Hui

Ovarian Neoplasms

• In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
• Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315)McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
• Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA BiomarkersBellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
• Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorMcNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
• Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
• NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8Anandhan A, Dodson M, Shakya A, Chen J, Liu P, Wei Y, Tan H, Wang Q, Jiang Z, Yang K, Garcia J, Chambers S, Chapman E, Ooi A, Yang-Hartwich Y, Stockwell B, Zhang D. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Science Advances 2023, 9: eade9585. PMID: 36724221, PMCID: PMC9891695, DOI: 10.1126/sciadv.ade9585.
• The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoHan C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
• Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
• Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
• Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
• Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043)Tymon-Rosario J, Manara P, Manavella D, Bellone S, Siegel E, Hartwich T, Harold J, Zammataro L, Yang-Hartwich Y, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043). Gynecologic Oncology 2022, 166: s30. DOI: 10.1016/s0090-8258(22)01262-8.
• Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorTymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.
• A Benzenesulfonamide-based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian CancerBi F, Jiang Z, Park W, Hartwich TMP, Ge Z, Chong KY, Yang K, Morrison MJ, Kim D, Kim J, Zhang W, Kril LM, Watt DS, Liu C, Yang-Hartwich Y. A Benzenesulfonamide-based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer. Molecular Cancer Therapeutics 2021, 20: molcanther.mct-21-0396-a.2021. PMID: 34625503, PMCID: PMC8643344, DOI: 10.1158/1535-7163.mct-21-0396.
• Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature ReviewBeroukhim G, Ozgediz D, Cohen PJ, Hui P, Morotti R, Schwartz PE, Yang-Hartwich, Vash-Margita A. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review. Journal Of Pediatric And Adolescent Gynecology 2021, 35: 359-367. PMID: 34843973, DOI: 10.1016/j.jpag.2021.11.003.
• Effect of exercise on peritoneal microenvironment and progression of ovarian cancer.Morrisson M, Bi F, Yang K, Cady S, Hartwich T, Cerchia A, Li Z, Kim J, Irwin M, Yang-Hartwich Y. Effect of exercise on peritoneal microenvironment and progression of ovarian cancer. American Journal Of Cancer Research 2021, 11: 5045-5062. PMID: 34765311, PMCID: PMC8569339.
• Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a modelHorst EN, Bregenzer ME, Mehta P, Snyder CS, Repetto T, Yang-Hartwich Y, Mehta G. Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. Acta Biomaterialia 2021, 132: 401-420. PMID: 33940195, PMCID: PMC8969826, DOI: 10.1016/j.actbio.2021.04.041.
• Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNAKang M, Tang B, Li J, Zhou Z, Liu K, Wang R, Jiang Z, Bi F, Patrick D, Kim D, Mitra AK, Yang-Hartwich Y. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular Cancer 2020, 19: 143. PMID: 32928232, PMCID: PMC7489042, DOI: 10.1186/s12943-020-01248-9.
• Abstract B49: Effects of exercise on ovarian cancer initiation and progressionBi F, Morrisson M, Cady S, Cerchia A, Yang K, Ling I, Yang-Hartwich Y. Abstract B49: Effects of exercise on ovarian cancer initiation and progression. Clinical Cancer Research 2020, 26: b49-b49. DOI: 10.1158/1557-3265.ovca19-b49.
• In vivo modeling of metastatic human high-grade serous ovarian cancer in miceKim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, Cheon DJ, Yang-Hartwich Y, Nakshatri H, Nephew KP, Behringer RR, Fernández FM, Cho CH, Vanderhyden B, Drapkin R, Bast RC, Miller KD, Karpf AR, Kim J. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLOS Genetics 2020, 16: e1008808. PMID: 32497036, PMCID: PMC7297383, DOI: 10.1371/journal.pgen.1008808.
• Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cellsKang M, Chong KY, Hartwich TMP, Bi F, Witham AK, Patrick D, Morrisson MJ, Cady SL, Cerchia AP, Kelk D, Liu Y, Nucci J, Madarikan O, Ueno D, Shuch BM, Yang-Hartwich Y. Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells. Oncogenesis 2020, 9: 55. PMID: 32471985, PMCID: PMC7260207, DOI: 10.1038/s41389-020-0243-y.
• An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt InhibitorsZhang W, Sviripa VM, Kril L, Yu T, Xie Y, Hubbard W, Sullivan P, Chen X, Zhan CG, Yang-Hartwich Y, Evers BM, Spear B, Gedaly R, Watt DS, Liu C. An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors. Journal Of Medicinal Chemistry 2019, 62: 11348-11358. PMID: 31774672, PMCID: PMC7560992, DOI: 10.1021/acs.jmedchem.9b01685.
• Abstract TMIM-084: PKCα INDUCES TWIST1 PHOSPHORYLATION AT SERINE 144 AND PROMOTES EMT IN OVARIAN CANCER CELLSTedja R, Roberts C, Cardenas C, Alvero A, Pitruzzello M, Yang-Hartwich Y, Glackin C, Mor G. Abstract TMIM-084: PKCα INDUCES TWIST1 PHOSPHORYLATION AT SERINE 144 AND PROMOTES EMT IN OVARIAN CANCER CELLS. Clinical Cancer Research 2019, 25: tmim-084-tmim-084. DOI: 10.1158/1557-3265.ovcasymp18-tmim-084.
• Abstract TMIM-075: MUTANT P53 PROMOTES THE INITIATION OF HIGH-GRADE SEROUS OVARIAN CARCINOMA FROM FALLOPIAN TUBE TUMOR PRECURSORS THROUGH ENHANCING TYROSINE RECEPTOR KINASE B SIGNALINGKang M, Chong K, Hartwich T, Cady S, Ncci J, Yang-Hartwich Y. Abstract TMIM-075: MUTANT P53 PROMOTES THE INITIATION OF HIGH-GRADE SEROUS OVARIAN CARCINOMA FROM FALLOPIAN TUBE TUMOR PRECURSORS THROUGH ENHANCING TYROSINE RECEPTOR KINASE B SIGNALING. Clinical Cancer Research 2019, 25: tmim-075-tmim-075. DOI: 10.1158/1557-3265.ovcasymp18-tmim-075.
• Abstract NT-116: TARGETING UNFOLDED PROTEIN RESPONSE FOR OVARIAN CANCER THERAPYPark W, Hartwich T, Chong K, Liu C, Watt D, Kim D, Yang-Hartwich Y. Abstract NT-116: TARGETING UNFOLDED PROTEIN RESPONSE FOR OVARIAN CANCER THERAPY. Clinical Cancer Research 2019, 25: nt-116-nt-116. DOI: 10.1158/1557-3265.ovcasymp18-nt-116.
• Tumor microenvironment and immunology of ovarian cancer: 12th Biennial Rivkin Center Ovarian Cancer Research SymposiumMitra AK, Yang-Hartwich Y. Tumor microenvironment and immunology of ovarian cancer: 12th Biennial Rivkin Center Ovarian Cancer Research Symposium. International Journal Of Gynecological Cancer 2019, 29: s12. PMID: 31462543, DOI: 10.1136/ijgc-2019-000666.
• Inhibition of Heat Shock Protein 90 suppresses TWIST1 TranscriptionChong KY, Kang M, Garofalo F, Ueno D, Liang H, Cady S, Madarikan O, Pitruzzello N, Tsai CH, Hartwich T, Shuch B, Yang-Hartwich Y. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription. Molecular Pharmacology 2019, 96: 168-179. PMID: 31175180, DOI: 10.1124/mol.119.116137.
• Protein kinase Cα–mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes itTedja R, Roberts CM, Alvero AB, Cardenas C, Yang-Hartwich Y, Spadinger S, Pitruzzello M, Yin G, Glackin CA, Mor G. Protein kinase Cα–mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it. Journal Of Biological Chemistry 2019, 294: 5082-5093. PMID: 30733340, PMCID: PMC6442047, DOI: 10.1074/jbc.ra118.005921.
• p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMTYang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Molecular Cancer Research 2019, 17: molcanres.0238.2018. PMID: 30131448, PMCID: PMC6800184, DOI: 10.1158/1541-7786.mcr-18-0238.
• Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitorsLi C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.
• Abstract A46: Hsp90 regulates Twist1 expression through STAT3 to induce epithelial-mesenchymal transition in ovarian cancerChong K, Garofalo F, Madarikan O, Pitruzzello N, Tsai C, Bingham J, Yang-Hartwich Y. Abstract A46: Hsp90 regulates Twist1 expression through STAT3 to induce epithelial-mesenchymal transition in ovarian cancer. Clinical Cancer Research 2018, 24: a46-a46. DOI: 10.1158/1557-3265.ovca17-a46.
• Abstract 5220: The role of brain-derived neurotrophic factor in ovarian cancer initiation and progressionKang M, Chong K, Hartwich T, Madarikan O, Nucci J, Cady S, Yang-Hartwich Y. Abstract 5220: The role of brain-derived neurotrophic factor in ovarian cancer initiation and progression. Cancer Research 2018, 78: 5220-5220. DOI: 10.1158/1538-7445.am2018-5220.
• Abstract 1969: PKCα-induced Twist1 phosphorylation is a novel regulator of Twist1 stabilizationTedja R, Alvero A, Cardenas C, Pitruzzello M, Yin G, Yang-Hartwich Y, Roberts C, Glackin C, Mor G. Abstract 1969: PKCα-induced Twist1 phosphorylation is a novel regulator of Twist1 stabilization. Cancer Research 2017, 77: 1969-1969. DOI: 10.1158/1538-7445.am2017-1969.
• Abstract AP16: THE CRITICAL ROLE OF P53–TWIST1 AXIS IN OVARIAN CANCER METASTASISYang-Hartwich Y, Tedja R, Bingham J, Soteras M, Alvero A, Mor G. Abstract AP16: THE CRITICAL ROLE OF P53–TWIST1 AXIS IN OVARIAN CANCER METASTASIS. Clinical Cancer Research 2017, 23: ap16-ap16. DOI: 10.1158/1557-3265.ovcasymp16-ap16.
• Abstract LB-352: p53-promoted Twist1 degradation inhibits EMT in ovarian cancer cellsYang-Hartwich Y, Tedja R, Bingham J, Gurrea Soteras M, Alvero A, Mor G. Abstract LB-352: p53-promoted Twist1 degradation inhibits EMT in ovarian cancer cells. Cancer Research 2016, 76: lb-352-lb-352. DOI: 10.1158/1538-7445.am2016-lb-352.
• Abstract 923: Exploring the role of the ovarian stromal extracellular matrix in early tumor developmentGoodner-Bingham J, Yang-Hartwich Y. Abstract 923: Exploring the role of the ovarian stromal extracellular matrix in early tumor development. Cancer Research 2016, 76: 923-923. DOI: 10.1158/1538-7445.am2016-923.
• Abstract 4201: Targeting tumor-associated neovasculature for delivery of optical enhancers detects ovarian cancer micrometastasisAlvero A, Lima E, Kim D, Orton S, Sumi N, Pitruzzello M, Yang-Hartwich Y, Silasi D, Fahmy T, Mor G. Abstract 4201: Targeting tumor-associated neovasculature for delivery of optical enhancers detects ovarian cancer micrometastasis. Cancer Research 2016, 76: 4201-4201. DOI: 10.1158/1538-7445.am2016-4201.
• TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In VivoAlvero AB, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, Cardenas C, Steinmacher S, Silasi DA, Brown D, Mor G. TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Molecular Cancer Therapeutics 2016, 15: 1279-1290. PMID: 27196760, DOI: 10.1158/1535-7163.mct-16-0005.
• Abstract A62: TRX-1 targets chemoresistant tumor-initiating cells and prolongs survival in a recurrent ovarian cancer animal model.Alvero A, Lima E, Pitruzzello M, Yang-Hartwich Y, Brown D, Heaton A, Mor G. Abstract A62: TRX-1 targets chemoresistant tumor-initiating cells and prolongs survival in a recurrent ovarian cancer animal model. Clinical Cancer Research 2016, 22: a62-a62. DOI: 10.1158/1557-3265.ovca15-a62.
• Abstract A61: Detection of ovarian cancer micrometastasis using nanoparticle-delivered probe targeted towards tumor-associated neovasculature.Alvero A, Lima E, Kim D, Orton S, Pitruzzello M, Yang-Hartwich Y, Silasi D. Abstract A61: Detection of ovarian cancer micrometastasis using nanoparticle-delivered probe targeted towards tumor-associated neovasculature. Clinical Cancer Research 2016, 22: a61-a61. DOI: 10.1158/1557-3265.ovca15-a61.
• Abstract AS16: Ovulation and extraovarian origin of ovarian cancerYang-Hartwich Y. Abstract AS16: Ovulation and extraovarian origin of ovarian cancer. Clinical Cancer Research 2015, 21: as16-as16. DOI: 10.1158/1557-3265.ovcasymp14-as16.
• Abstract LB-014: Targeting p53 aggregation in ovarian cancer chemoresistant cellsYang-Hartwich Y, Cardenas C, Pitruzzello M, Lima E, Alvero A, Mor G. Abstract LB-014: Targeting p53 aggregation in ovarian cancer chemoresistant cells. 2015, lb-014-lb-014. DOI: 10.1158/1538-7445.am2015-lb-014.
• Abstract 1519: Cantrixil targets ovarian cancer stem cells and prevents recurrence in a cisplatin-resistant animal modelMor G, Lima E, Sumi N, Pitruzzello M, Yang-Hartwich Y, Brown D, Heaton A, Alvero A. Abstract 1519: Cantrixil targets ovarian cancer stem cells and prevents recurrence in a cisplatin-resistant animal model. 2015, 1519-1519. DOI: 10.1158/1538-7445.am2015-1519.
• Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer RecurrenceSumi N, Lima E, Pizzonia J, Orton S, Craveiro V, Joo W, Holmberg J, Gurrea M, Yang-Hartwich Y, Alvero A, Mor G. Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence. Journal Of Visualized Experiments 2014 DOI: 10.3791/51815-v.
• Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer RecurrenceSumi NJ, Lima E, Pizzonia J, Orton SP, Craveiro V, Joo W, Holmberg JC, Gurrea M, Yang-Hartwich Y, Alvero A, Mor G. Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence. Journal Of Visualized Experiments 2014, 51815. PMID: 25407815, PMCID: PMC4353409, DOI: 10.3791/51815.
• Abstract 1974: Ovulatory wound: the site of origin for ovarian serous carcinomaYang-Hartwich Y, Gurrea M, Sumi N, Holmberg J, Craveiro V, Alvero A, Mor G. Abstract 1974: Ovulatory wound: the site of origin for ovarian serous carcinoma. 2014, 1974-1974. DOI: 10.1158/1538-7445.am2014-1974.
• p53 protein aggregation promotes platinum resistance in ovarian cancerYang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2014, 34: 3605-3616. PMID: 25263447, DOI: 10.1038/onc.2014.296.
• Detection of p53 Protein Transcriptional Activity by Chromatin ImmunoprecipitationYang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, Mor G. Detection of p53 Protein Transcriptional Activity by Chromatin Immunoprecipitation. 2014, 1219: 87-93. PMID: 25308264, DOI: 10.1007/978-1-4939-1661-0_8.
• Detection of p53 Protein Aggregation in Cancer Cell Lines and Tumor SamplesYang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, Mor G. Detection of p53 Protein Aggregation in Cancer Cell Lines and Tumor Samples. 2014, 1219: 75-86. PMID: 25308263, DOI: 10.1007/978-1-4939-1661-0_7.
• Ovulation and extra-ovarian origin of ovarian cancerYang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB, Mor G. Ovulation and extra-ovarian origin of ovarian cancer. Scientific Reports 2014, 4: 6116. PMID: 25135607, PMCID: PMC4137344, DOI: 10.1038/srep06116.
• Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatmentCraveiro V, Yang‐Hartwich Y, Holmberg J, Sumi N, Pizzonia J, Griffin B, Gill S, Silasi D, Azodi M, Rutherford T, Alvero A, Mor G. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine 2013, 2: 987-987. PMCID: PMC3892404, DOI: 10.1002/cam4.165.
• Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatmentCraveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine 2013, 2: 751-762. PMID: 24403249, PMCID: PMC3892380, DOI: 10.1002/cam4.115.
• Abstract LB-286: ME-344 delays tumor kinetics in an ovarian cancer in vivo recurrence model.Alvero A, Sumi N, Craveiro V, Joo W, Yang-Hartwich Y, Mor G. Abstract LB-286: ME-344 delays tumor kinetics in an ovarian cancer in vivo recurrence model. Cancer Research 2013, 73: lb-286-lb-286. DOI: 10.1158/1538-7445.am2013-lb-286.
• TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrenceChefetz I, Alvero A, Holmberg J, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Soteras M, Aldo P, Mor G. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 2013, 12: 511-521. PMID: 23324344, PMCID: PMC3587452, DOI: 10.4161/cc.23406.
• Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potentialYin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G. Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2012, 32: 39-49. PMID: 22349827, PMCID: PMC3703656, DOI: 10.1038/onc.2012.33.
• An In Vitro Model for the Study of Human ImplantationHolmberg JC, Haddad S, Wünsche V, Yang Y, Aldo PB, Gnainsky Y, Granot I, Dekel N, Mor G. An In Vitro Model for the Study of Human Implantation. American Journal Of Reproductive Immunology 2011, 67: 169-178. PMID: 22151560, PMCID: PMC3703643, DOI: 10.1111/j.1600-0897.2011.01095.x.
• Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian CancerSteffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G. Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer. Journal Of Oncology 2011, 2011: 620523. PMID: 21904548, PMCID: PMC3166719, DOI: 10.1155/2011/620523.
• Ovarian cancer stem cells and inflammationMor G, Yin G, Chefetz I, Yang Y, Alvero A. Ovarian cancer stem cells and inflammation. Cancer Biology & Therapy 2011, 11: 708-713. PMID: 21317559, PMCID: PMC3100563, DOI: 10.4161/cbt.11.8.14967.